Brief: Ipsen Q3 Revenue EUR 915 Million, Upgrades 2025 Outlook
Oct 22 (Reuters) - Ipsen SA IPN.PA: IPSEN Q3 REVENUE EUR 915 MILLION IPSEN SA - OUTLOOK 2025: TOTAL SALES GROWTH OF AROUND 10.0%(2) AT CER (PRIOR GUIDANCE GREATER THAN 7.0%) IPSEN SA - OUTLOOK 2025: CORE OPERATING MARGIN OF AROUND 35.0% OF TOTAL SALES (PRIOR GUIDANCE GREATER THAN 32.0%) Source text: ID:nGNECdcLS Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients